Conferences
ASCO GU 2024: Harnessing the Power: Biologic Basis of Pairing and Sequencing Checkpoints with Other Therapy
January 28, 2024
ASCO GU 2024: Association Between SPECT/CT Total Tumor Volume and New Lesions in Early Cycles of 177Lu-PSMA-617 and PFS and OS in Men with mCRPC
January 28, 2024
ASCO GU 2024: Neoadjuvant Combined Chemotherapy and Immunotherapy for Upper Tract Urothelial Carcinoma: Preliminary Results From a Phase II Study
January 28, 2024
ASCO GU 2024: Implementation Outcomes of a Multidisciplinary Approach for Lu177-PSMA-617 Therapy
January 28, 2024
ASCO GU 2024: Evaluating Clinical Outcomes with Systemic Therapy Given After Progression on PSMA Radioligand Therapy in Patients with mCRPC
January 28, 2024
ASCO GU 2024: Setting the Stage: Biochemical Recurrence After Local Treatment for Prostate Cancer
January 28, 2024
ASCO GU 2024: Low and High Volume Disease in mHSPC, from CHAARTED to PSMA-PET: An International Multicenter Retrospective Study
January 28, 2024
ASCO GU 2024: Neoadjuvant Nivolumab + Ipilimumab in Cisplatin-Ineligible Patients with Upper Tract Urothelial Cancer: Updated Results
January 28, 2024
ASCO GU 2024: Patient Reported Outcomes Among Patients with mCRPC by HRR Mutations Gene Clusters: Findings from the Phase 3 TALAPRO-2 Study Cohort 2
January 28, 2024